Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (141-150 of 225) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
Cancer|May 1, 2012
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancerJames P Stevenson, Corey J Langer, Robert A Somer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
Cancer|September 11, 2020
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trialsHossein Borghaei, Corey J Langer, Luis Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility CriteriaPhilip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
International Journal of Radiation Oncology, Biology, Physics|June 5, 2012
Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implicationsMichael J Eblan, Michael N Corradetti, J Nicholas Lukens, et al.
International Journal of Radiation Oncology, Biology, Physics|August 2, 2025
Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911Corey J Langer, Jonathan Harris, Eric M Horwitz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapyChao Hui Huang, Michael M Millenson, Eric J Sherman, et al.
Pageof 23

Showing results (141-150 of 225) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
Cancer|May 1, 2012
Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancerJames P Stevenson, Corey J Langer, Robert A Somer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
JAMA Oncology|February 21, 2020
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialSalma K Jabbour, Abigail T Berman, Roy H Decker, et al.
Cancer|September 11, 2020
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trialsHossein Borghaei, Corey J Langer, Luis Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2018
Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility CriteriaPhilip Bonomi, Gideon Blumenthal, Andrea Stern Ferris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerDaniel D Karp, Luis G Paz-Ares, Silvia Novello, et al.
International Journal of Radiation Oncology, Biology, Physics|June 5, 2012
Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implicationsMichael J Eblan, Michael N Corradetti, J Nicholas Lukens, et al.
International Journal of Radiation Oncology, Biology, Physics|August 2, 2025
Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911Corey J Langer, Jonathan Harris, Eric M Horwitz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapyChao Hui Huang, Michael M Millenson, Eric J Sherman, et al.
Pageof 23